GRAIL GRAL
United StatesHealthcare · Diagnostics & ResearchUSD
112.40 USD (−15.4%)
10 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
GRAIL, Inc. is a healthcare diagnostics company that develops and commercializes early cancer detection tests based on blood analysis, with its main product being the Galleri test.
Key points
from its scores- ✓Strong growth8.8
- ✕Unfavourable risk and backdrop0.0
- ✕Little or no dividend0.5
- ✕Demanding valuation0.8
AI analysis
bottom line, main risk, context and newsHold only if you believe in the long-term potential of Galleri; current fundamentals do not justify entry.
GRAIL shows strong revenue growth (25.7%) but remains unprofitable, with deeply negative operating margins (-332%) and a ROIC of -20.8%, reflecting a business in investment phase with demanding valuation (FCF yield -1.74%).
The main risk is dependence on clinical adoption and reimbursement of its Galleri test, along with sustained cash burn requiring additional financing.
Context and risks
GRAIL operates in the healthcare diagnostics sector in the US, where regulatory and Medicare/Medicaid reimbursement pressure on cancer screening tests is a structural risk. Its business model depends on clinical adoption and reimbursement of its flagship Galleri test, adding business model risk to a company that is not yet profitable.
Is GRAIL stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 951% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 2.3 | 4.1 | −43% |
| Price / sales | 35.9 | 3.4 | +951% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 0.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 112.40 USD, −15.4% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 2.5 (sector 5.5), Growth 8.8 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −16.1
- EV / EBITDA
- −13.6
- Price / book
- 2.3
- Price / sales
- 35.9
- Market cap
- 5.9B USD
- Enterprise value
- 5.2B USD
Profitability
- ROE
- −16.1%
- ROA
- −12.0%
- ROIC (approx.)
- −20.8%
- Gross margin
- 49.7%
- Operating margin
- −332.0%
- Net margin
- −236.9%
- Free cash flow
- −103.6M USD
- FCF yield
- −1.7%
Solvency
- Total debt
- 91.3M USD
- Net debt
- −770.3M USD
- Cash
- 861.6M USD
- EBITDA
- −378.5M USD
- Net debt / EBITDA
- 2.04
- Debt / equity
- 3.59
- Current ratio
- 10.95
- Quick ratio
- 10.55
Growth
- Revenue growth
- +25.7%
- EPS (TTM)
- −9.70 USD
- EPS (forward)
- −8.25 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Beta
- 2.84
- Analyst consensus
- Buy (10)
- Target price
- 112.40 USD
- 52-week range
- 41.50 – 166.47
Recent news
All GRAL news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about GRAIL
Is GRAIL stock cheap or expensive?
On Price / sales, it trades 951% above the Healthcare median. Valuation score: 0.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 112.40 USD, −15.4% versus the price. This is not investment advice.
What score does GRAIL get on MeridIAn Screener?
It scores 3.1 out of 10, rank 2,078 of 2,130 (better than 2% of the companies analysed). Its strongest category is Growth (8.8) and its weakest, Risk & Context (0.0). Analysis of 08/10/2026.
How much is GRAIL worth on the stock market?
Its market capitalisation is 5.9B USD and its enterprise value, debt included, is 5.2B USD.
How much debt does GRAIL have?
It has more cash than debt: net cash of 770.3M USD.
Does GRAIL pay a dividend?
It pays no dividend, or almost none.
How has GRAIL stock performed over the last year?
It has risen 101.0% over the last year, excluding dividends. Over the last 52 weeks it has traded between 41.50 and 166.47 USD. Past performance does not guarantee future results.
What do analysts think of GRAIL?
10 analysts cover it; their average recommendation is “Buy” and their average target is 112.40 USD (−15.4% versus the price). It is an estimate, not market data.